---
schema_version: "secwatch.filing_event.v1"
accession: "0001724521-26-000037"
form_type: "8-K"
ticker: "RCUS"
cik: "0001724521"
company_name: "Arcus Biosciences, Inc."
filed_at: "2026-06-12T20:12:40+00:00"
generated_at: "2026-06-12T20:27:08.639241+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.0
calibrated_materiality_score: 0.0
confidence: "high"
source: SEC EDGAR
---

# Arcus Biosciences stockholders elect four Class II directors, ratify auditor, approve say-on-pay

## Summary
- Elected Class II directors: Dietmar Berger (85.9M for), David Lacey (86.0M), Nicole Lambert (92.7M), Johanna Mercier (85.9M); ~13.6M broker non-votes.
- Ratified Ernst & Young as auditor for FY2026: 112.9M for, 4.8M against, 0.2M abstain.
- Advisory say-on-pay approved: 94.9M for, 9.3M against, 29.7K abstain; 13.6M broker non-votes.

## SEC filing metadata
- accession: 0001724521-26-000037
- form_type: 8-K
- ticker: RCUS
- cik: 0001724521
- company_name: Arcus Biosciences, Inc.
- filed_at: 2026-06-12T20:12:40+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.0
- calibrated_materiality_score: 0.0
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000037/0001724521-26-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000037/rcus-20260611.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001724521-26-000037
- JSON: https://secwatch.observer/filing/0001724521-26-000037.json
- Plain text: https://secwatch.observer/filing/0001724521-26-000037.txt

## Key facts
- Shareholder Votes
  Arcus Biosciences, Inc. shareholders approved The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement at the 2026-06-11 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 3 : The approval, on an advisory basis, of the compensation of the Company's named executive officers as disclosed in the Proxy Statement: Votes For Votes Against Abstentions Broker Non-Votes 94,920,421 9,337,368 29,741 13,573,227
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000037/0001724521-26-000037-index.htm
- Shareholder Votes
  Arcus Biosciences, Inc. shareholders approved The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified at the 2026-06-11 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 1 : The election of Class II directors to hold office until the 2029 Annual Meeting of Stockholders and until its successor is duly elected and qualified: Nominee Votes For Votes Withheld Broker Non-Votes Dietmar Berger, M.D., Ph.D. 85,949,508 18,338,022 13,573,227 David Lacey, M.D. 85,974,583 18,312,947 13,573,227 Nicole Lambert 92,653,341 11,634,189 13,573,227 Johanna Mercier 85,941,754 18,345,776 13,573,227
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000037/0001724521-26-000037-index.htm
- Shareholder Votes
  Arcus Biosciences, Inc. shareholders approved The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026 at the 2026-06-11 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-11
  source text: Proposal 2 : The ratification of the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 112,905,582 4,767,430 187,745
  evidence_url: https://www.sec.gov/Archives/edgar/data/1724521/000172452126000037/0001724521-26-000037-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.